NeuroSearch to present at the Bear Stearns Healthcare Conference in New York

NeuroSearch (NEUR) will present at the Bear Stearns Healthcare Conference to be
held from 10-11 September in New York. 

The presentation will be held by Flemming Pedersen, CEO, and is scheduled for:

Monday 10 September 2007 from 8:30 am to 8:55 am

A PowerPoint version of the presentation will be accessible on our website
www.neurosearch.com just prior to the presentation at the conference. 


Contact person: 
Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate
Communications - telephone: +45 4460 8212 or +45 4017 5103 



NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the
OMX Nordic Exchange Copenhagen A/S. Our core business covers the development of
novel drugs, based on a broad and well-established drug discovery platform
focusing on ion channels and CNS disorders. A substantial part of the company's
activities are partner financed through a broad alliance with GlaxoSmithKline
(GSK) and collaborations with among others Abbott and Astellas. The drug
pipeline comprises 11 clinical (Phase I-III) development programmes: ACR16 in
Huntington's disease (Phase III preparation), tesofensine in obesity/type 2
diabetes (Phase II), NS2359 in depression (Phase II) and ADHD (Phase II) in
partnership with GSK, NS1209 in epilepsy and pain (Phase II), ABT-894 in ADHD
(Phase II) and pain (Phase I) in partnership with Abbott, ACR16 in
schizophrenia (Phase I) in partnership with Astellas, ACR325 in Parkinson's
disease and bipolar disorder (Phase I) and ABT-107 as well as ABT-560 for the
treatment of various CNS diseases - both (Phase I) in collaboration with
Abbott. In addition, NeuroSearch has a broad portfolio of preclinical drug
candidates and holds equity interests in several biotech companies.